ResMed CFO Brett Sandercock Retires After 20 Years; Aaron Bloomer Appointed
ResMed CFO Brett Sandercock retires May 4, 2026 after 27 years, including 20 as CFO, and will be succeeded by Exact Sciences finance chief Aaron Bloomer. The company reiterated fiscal 2026 guidance of 62-63% gross margin, 19-20% SG&A, 6-7% R&D and a 21-23% tax rate.
1. CFO Transition
Brett Sandercock will retire as ResMed’s Chief Financial Officer effective May 4, 2026 after 27 years with the company, including 20 leading its finance organization. He will continue as an advisor to the CEO through calendar year 2027 to support a smooth handover.
2. Bloomer's Background
Aaron Bloomer joins ResMed from Exact Sciences, where he served as CFO and helped deliver strong revenue growth, margin expansion and free cash flow improvements. He brings more than 17 years of global finance and operating leadership, with prior senior roles at Baxter International and 3M.
3. Fiscal 2026 Guidance
Alongside the leadership update, ResMed reiterated its full-year fiscal 2026 targets: 62-63% gross margin, 19-20% SG&A expenses, 6-7% R&D investment and an effective tax rate of 21-23%, underscoring continued financial discipline.